BLASUBCUTANEOUSSOLUTION2 Generics Approved
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
BASAGLAR (insulin glargine) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 2015.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BASAGLAR (insulin glargine) is a long-acting basal insulin analog approved by FDA in 2015 for subcutaneous injection. It is a biosimilar referencing Lantus and is indicated for glycemic control in patients with type 1 and type 2 diabetes mellitus. The drug works by binding to insulin receptors to facilitate glucose uptake and promote anabolic effects in muscle and fat tissue.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), indicating stable but increasingly defensive team positioning in the basal insulin market.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Started Aug 2025
877 enrolled
Diabetes Mellitus, Type 1
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
Started Apr 2024
429 enrolled
Diabetes, Type 2
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Started Feb 2024
485 enrolled
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Started Nov 2023
546 enrolled
Type 2 Diabetes
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Started Apr 2023
2,749 enrolled
Type 2 DiabetesObesityOverweight or Obesity+3 more
Worked on BASAGLAR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.